Prophylactic aspirin and risk of peptic ulcer bleeding

作者：J Weil, Duncan G. Colin-Jones, M. J. S. LANGMAN, David H. Lawson, Richard Logan, Michael S. Murphy, M. D. Rawlins, Martin P. Vessey, Paul Wainwright · 发表于：BMJ · 年份：1995 · DOI：10.1136/bmj.310.6983.827 · 被引用次数：568 · 研究领域：Gastrointestinal Bleeding Diagnosis and Treatment、Antiplatelet Therapy and Cardiovascular Diseases、Helicobacter pylori-related gastroenterology studies

OBJECTIVE: To determine the risks of hospitalisation for bleeding peptic ulcer with the current prophylactic aspirin regimens of 300 mg daily or less. DESIGN: A case-control study with hospital and community controls. SETTING: Hospitals in Glasgow, Newcastle, Nottingham, Oxford, and Portsmouth. SUBJECTS: 1121 patients with gastric or duodenal ulcer bleeding matched with hospital and community controls. RESULTS: 144 (12.8%) cases had been regular users of aspirin (taken at least five days a week for at least the previous month) compared with 101 (9.0%) hospital and 77 (7.8%) community controls. Odds ratios were raised for all doses of aspirin taken, whether compared with hospital or community controls (compared with combined controls: 75 mg, 2.3 (95% confidence interval 1.2 to 4.4); 150 mg, 3.2 (1.7 to 6.5); 300 mg, 3.9 (2.5 to 6.3)). Results were not explained by confounding influences of age, sex, prior ulcer history or dyspepsia, or concurrent non-aspirin non-steroidal anti-inflammatory drug use. Risks seemed particularly high in patients who took non-aspirin non-steroidal anti-inflammatory drugs concurrently. CONCLUSION: No conventionally used prophylactic aspirin regimen seems free of the risk of peptic ulcer complications.